EARLY IMPROVEMENT WITH AGOMELATINE IS PREDICTIVE OF TREATMENT RESPONSE AT WEEK 6 IN A LARGE UNCONTROLLED OBSERVATIONAL STUDY OF OUTPATIENTS WITH MDD

被引：0
|
作者：
Gorwood, P. [1 ]
Courtet, P. [2 ]
Bayle, F. J. [3 ]
Vaiva, G. [4 ]
Corruble, E. [5 ]
Llorca, P. -M. [6 ]
机构：
[1] Hosp St Anne, CMME, Paris, France
[2] Univ Montpellier, Dept Psychiat, F-34059 Montpellier, France
[3] Paris Descartes Univ, SHU St Anne, Paris, France
[4] Univ Lille, Dept Psychiat, Lille, France
[5] Krelin Bicetre Hosp, Dept Psychiat, Le Kremlin Bicetre, France
[6] Univ Clermont Ferrand, Dept Psychiat, Clermont Ferrand, France
来源：
EUROPEAN PSYCHIATRY | 2012年 / 27卷
关键词：
D O I：
暂无
中图分类号：
R749 [精神病学];
学科分类号：
100205 ;
摘要：
P-487
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Agomelatine for the Treatment of Patients with Fibromyalgia and Depressive Symptomatology: An Uncontrolled, 12-Week, Pilot Study
    Calandre, E. P.
    Slim, M.
    Garcia-Leiva, J. M.
    Rodriguez-Lopez, C. M.
    Torres, P.
    Rico-Villademoros, F.
    PHARMACOPSYCHIATRY, 2014, 47 (02) : 67 - 72
  • [2] Agomelatine in the Treatment of Fibromyalgia A 12-Week, Open-Label, Uncontrolled Preliminary Study
    Bruno, Antonio
    Mico, Umberto
    Lorusso, Simona
    Cogliandro, Nadia
    Pandolfo, Gianluca
    Caminiti, Maurizio
    Zoccali, Rocco A.
    Muscatello, Maria R. A.
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2013, 33 (04) : 507 - 511
  • [3] RPS6KA5 methylation predict response to 6-week treatment for adolescent MDD patients
    Xu, Peiwei
    Tao, Yuanmei
    Zhang, Hang
    Jin, Meijiang
    Xu, Hanmei
    Zou, Shoukang
    Deng, Fang
    Huang, Lijuan
    Zhang, Hong
    Wang, Xiaolan
    Tang, Xiaowei
    Dong, Zaiquan
    Wang, Yanping
    Yin, Li
    Sun, Xueli
    BMC PSYCHIATRY, 2022, 22 (01)
  • [4] RPS6KA5 methylation predict response to 6-week treatment for adolescent MDD patients
    Peiwei Xu
    Yuanmei Tao
    Hang Zhang
    Meijiang Jin
    Hanmei Xu
    Shoukang Zou
    Fang Deng
    Lijuan Huang
    Hong Zhang
    Xiaolan Wang
    Xiaowei Tang
    Zaiquan Dong
    Yanping Wang
    Li Yin
    Xueli Sun
    BMC Psychiatry, 22
  • [5] Early symptom non-improvement and aggravation are associated with the treatment response to SSRIs in MDD: a real-world study
    Yuan, Hsinsung
    Zhu, Xiao
    Luo, Qiang
    Halim, Alice
    Halims, Michael
    Yao, Hao
    Cai, Yiyun
    Shi, Shenxun
    NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2019, 15 : 957 - 966
  • [6] IS RESPONSE TO LINACLOTIDE AFTER 4 WEEKS OF TREATMENT PREDICTIVE OF 12-WEEK IMPROVEMENT?
    Chey, W.
    Lavins, B.
    Shiff, S.
    MacDougall, J.
    Kurtz, C.
    Currie, M.
    Johnston, J.
    GUT, 2014, 63 : A197 - A198
  • [7] RANDOMIZED, DOUBLE-BLIND, STUDY OF VORTIOXETINE VERSUS AGOMELATINE IN ADULTS WITH MDD AFTER INADEQUATE RESPONSE TO SSRI OR SNRI TREATMENT
    Haggstrom, L.
    Nielsen, R. Z.
    Dragheim, M.
    EUROPEAN PSYCHIATRY, 2013, 28
  • [8] Predictive Modeling of Response to Pregabalin for the Treatment of Neuropathic Pain Using 6-Week Observational Data: A Spectrum of Modern Analytics Applications
    Emir, Birol
    Johnson, Kjell
    Kuhn, Max
    Parsons, Bruce
    CLINICAL THERAPEUTICS, 2017, 39 (01) : 98 - 106
  • [9] Early Improvement in One Week Predicts the Treatment Response to Escitalopram in Patients with Social Anxiety Disorder: A Preliminary Study
    Oh, Kang-Seob
    Shin, Eunsook
    Ha, Juwon
    Shin, Dongwon
    Shin, Youngchul
    Lim, Se-Won
    CLINICAL PSYCHOPHARMACOLOGY AND NEUROSCIENCE, 2016, 14 (02) : 161 - 167
  • [10] A randomised, double-blind, study of vortioxetine versus agomelatine in adults with major depressive disorder (MDD) with inadequate response to SSRI/SNRI treatment
    Haggstrom, L.
    Nielsen, R. Z.
    Danchenko, N.
    Poulsen, L.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2013, 23 : S412 - S412
12345